J7647 Isoetharine HCl (HCPCS) Reimbursement | OpenPayer

Summary & Overview

HCPCS J7647: Isoetharine HCl Inhalation Solution, Compounded, Per mg

HCPCS Level II code J7647 designates isoetharine hydrochloride inhalation solution as a compounded, concentrated product billed per milligram when administered through durable medical equipment. The code is used for invoicing compounded inhalation bronchodilator therapy delivered via DME in home or outpatient settings, and it captures a niche clinical supply type important for patients requiring individualized inhaled dosing.

Key payers referenced in national billing contexts include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and reimbursement practices for compounded inhalation solutions frequently vary by payer due to compound formulation, DME routing, and documentation requirements.

Readers will gain a concise overview of the code's clinical purpose and billing context, intended sites of service, typical documentation elements, and areas where payer policy differences commonly arise. The publication includes benchmark comparisons, policy and coverage considerations, and clinical context to help billing managers, revenue cycle staff, and clinical pharmacists understand how J7647 is used within national payer landscapes. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7647HCPCS Level IIisoetharineinhalation therapycompounded medicationdurable medical equipmentpharmacy billingDME-administered drugs

Billing Code Overview

HCPCS Level II code J7647 represents Isoetharine hydrochloride inhalation solution, compounded product, concentrated form, administered through durable medical equipment (DME), billed per milligram. This code applies to compounded, concentrated inhalation solutions of isoetharine HCl delivered via DME for inhalation therapy.

Service Type: Inhalation pharmacologic therapy, compounded medication

Typical Site of Service: Home or outpatient setting where durable medical equipment is used for aerosolized medication administration

Clinical & Coding Specifications

Clinical Context

A patient with acute bronchospasm from asthma or chronic obstructive pulmonary disease (COPD) presents to a durable medical equipment (DME)-associated outpatient infusion or respiratory therapy area for administration of a compounded inhalation bronchodilator. The service involves preparation and administration of J7647 (isoetharine HCl inhalation solution, compounded, concentrated form, per mg) delivered via the patient’s nebulizer or ventilator circuit associated with DME. Typical workflow: clinician or pharmacist compounds the concentrated solution per prescription, performs dose calculation and sterile preparation, documents lot and mg dispensed, RN or respiratory therapist verifies the medication and administers via DME device, monitors the patient for bronchodilator response and adverse effects (tachycardia, tremor), and documents administration and patient tolerance in the medical record. Billing is submitted under the HCPCS Level II code J7647 with appropriate modifiers reflecting special circumstances (for example, unusual service complexity, patient transfer, or payer-specific program codes). Typical site of service is a DME-associated outpatient clinic, ambulatory infusion center with respiratory therapy services, home health setting when DME is used for administration, or hospital outpatient department when an outpatient DME device is used for inhalation therapy. The typical patient is an adult or pediatric patient with symptomatic bronchospasm requiring a compounded inhaled short-acting beta-agonist due to allergy, supply shortage, or dose customization not available in commercially manufactured preparations.

Coding Specifications

Modifier	Description	When to Use

HCPCS Level II J1071: Injection, Testosterone Cypionate, 1 mg

HCPCS-J2410-OXYMORPHONE-INJECTION-UP-TO-1-MG

HCPCS J2410: Oxymorphone Injection, Up to 1 mg

HCPCS-J2680-FLUPHENAZINE-DECANOATE-INJECTION-UP-TO-25-MG

HCPCS J2680: Fluphenazine Decanoate Injection, up to 25 mg

HCPCS-J7511-LYMPHOCYTE-IMMUNE-GLOBULIN-ANTITHYMOCYTE-RABBIT-25MG

HCPCS Level II J7511: Lymphocyte Immune Globulin, Rabbit, 25 mg

HCPCS-J2724-PROTEIN-C-CONCENTRATE-INJECTION-10-IU

HCPCS J2724: Injection, Human Protein C Concentrate, 10 IU

HCPCS-J0641-LEVOLEUCOVORIN-INJECTION-05-MG

HCPCS J0641: Levoleucovorin Injection, 0.5 mg

HCPCS-J1945-LEPIRUDIN-INJECTION-50MG

HCPCS J1945: Injection, lepirudin, 50 mg

HCPCS-J0601-SEVELAMER-CARBONATE-ORAL-20MG-ESRD-DIALYSIS

HCPCS Level II J0601: Sevelamer Carbonate Oral 20 mg for ESRD on Dialysis

HCPCS-J3465-VORICONAZOLE-INJECTION-10MG

HCPCS J3465: Voriconazole Injection, 10 mg

HCPCS-J0350-ANISTREPLASE-INJECTION-30-UNITS

HCPCS J0350: Injection, Anistreplase, per 30 Units

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`103K00000X`	Emergency Medicine	Emergency clinicians frequently manage acute bronchospasm and arrange DME-associated inhalation therapy.
`207R00000X`	Pulmonary Disease	Pulmonologists prescribe and oversee compounded inhalation bronchodilator therapy for complex respiratory disease.
`363A00000X`	Respiratory Therapy	Registered respiratory therapists perform administration and monitoring of nebulized compounded medications via DME.
`193200000X`	Nurse Practitioner	NPs often manage chronic respiratory conditions and coordinate compounded inhalation treatments.
`333600000X`	Clinical Pharmacist	Pharmacists compound the concentrated isoetharine solution and verify dosing and sterile technique.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J45.901`	Unspecified asthma, uncomplicated	Asthma with acute bronchospasm is a primary indication for inhaled short-acting beta-agonist therapy such as compounded isoetharine.
`J44.1`	Chronic obstructive pulmonary disease with (acute) exacerbation	COPD exacerbations frequently require nebulized bronchodilator therapy administered via DME devices.
`J46`	Status asthmaticus	Severe, life-threatening asthma requiring intensive bronchodilator therapy; compounded agents may be used when standard formulations are unavailable.
`R06.2`	Wheezing	Symptom code used when bronchodilator therapy is provided for symptomatic relief.
`J98.01`	Acute bronchospasm	Direct clinical indication for administration of a bronchodilator inhalation solution.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction, eg, inhaled bronchodilator; initial administration	Commonly billed for the professional service of administering a nebulized bronchodilator such as a compounded `J7647` preparation.
`94644`	Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	Performed when training or competency assessment is needed for patient use of DME nebulizer delivering the compounded solution.
`81025`	Urinalysis, automated, with microscopy	Example of point-of-care testing that may be performed in the same visit for monitoring (not directly related to `J7647` but commonly ordered during acute visits).
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Typical E/M visit associated with assessment prior to prescribing or administering compounded inhalation therapy.
`99199`	Unlisted special service, procedure or report	Used when a payer requires an unlisted code for novel or heavily customized compounding services not covered by standard codes.

Note: If a payer requires separate billing for the medication product, J7647 is used for the drug item while the CPT codes above capture related professional services and procedures.

`22`	Increased procedural services	Use when preparation or administration of `J7647` requires significantly greater resources than typical (extensive compounding, extended monitoring) and documentation supports increased work.
`23`	Unusual anesthesia circumstances	Use when general anesthesia is required for administration of inhaled therapy (rare in this context) and anesthesia services meet criteria.
`52`	Reduced services	Use when the compounded inhalation product is partially administered or service is curtailed and documentation explains reduction.
`53`	Discontinued procedure	Use when administration was started but discontinued due to an adverse event or patient intolerance prior to completion.
`54`	Surgical care only	Use when postoperative care is billed separately and another provider bills the inhalation administration during a surgical global period (rare for this service).
`55`	Postoperative management only	Use when only postoperative management for a related procedure is provided and inhalation therapy is part of that postoperative care.
`56`	Preoperative management only	Use when only preoperative management is billed and inhalation therapy occurs as preop treatment.
`62`	Two surgeons	Use when two qualified clinicians are required and documented for the administration/management of complex airway therapy.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Use if an advanced practice clinician assists in the procedure-related airway management when billing rules permit.
`QX`	CRNA service with an anesthesiologist present	Use when a certified registered nurse anesthetist provides anesthesia care in presence of an anesthesiologist related to administration circumstances.

OpenPayer